| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On September 28, 2025, Jaguar Health, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with Brown Stone Capital Limited (the "Investor"), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the "Private Placement") (i) 161,583 shares ("Shares") of the Company's voting common stock, par value 0.0001 (the "Common Stock") and (ii) 479,442 pre-funded warrants (the "Pre-Funded Warrants") to purchase shares of Common Stock (the "Pre-Funded Warrant Shares" and together with the Shares and the Pre-Funded Warrants, the "Securities").
The purchase price of the Shares is $1.56 per share and the purchase price for the Pre-Funded Warrants is $1.56 minus $0.0001. The Company intends to use the proceeds from the Private Placement for working capital and general corporate purposes and repayment of existing convertible notes. The Pre-Funded Warrants will be exercisable, in whole or in part, at any time after the closing of the Private Placement.
Posted In: JAGX
